Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-2

Holy Moly!

Key Highlights
• AstraZeneca progresses to routine use: 9 APAS® Independence installed across global sites
• Novo Nordisk initial purchase order, new global pharmaceutical customer: Group wide evaluation of
APAS® Independence for their global manufacturing network
• Sales opportunity from existing customers exceeds $40m: 5 existing customers represent opportunity of
60-80 APAS® instruments1 - equating to $36-48 million of potential upfront sales revenue and $7-9 million in
annual recurring revenues2
• New contact plate analysis module doubles APAS® capability: Contact plates account for roughly 50% of
culture plates used in environmental monitoring - instrument hardware and software completed, AI analysis
module and launch targeted for August 2025
• Positive financial start to FY26 supported by sales pipeline & receivables: 30 June 2025 cash balance
of $1.3 million, and $3.8 million in known/committed cash inflows expected over the next two quarters